目的 为临床合理使用替考拉宁以及更好地管理接受替考拉宁治疗的患者。方法 从药学角度对2022年日本《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》(简称《指南》)涉及替考拉宁治疗的9个临床问题进行解读。结果 《指南》指出药-时曲线下面积/最小抑菌浓度是替考拉宁的关键药动学/药效学参数。替考拉宁治疗药物监测(TDM)的目的是明确目标谷浓度(C_min),对于严重或复杂的耐甲氧西林金黄色葡萄球菌(MRSA)感染,指南建议替考拉宁C_min为20~40 mg/L。肾功能正常或轻度受损的非复杂性的MRSA感染,目标C_min为15~30 mg/L。严重和/或复杂性MRSA感染,如感染性心内膜炎和骨髓炎,替考拉宁C_min为20~40 mg/L。结论 《指南》针对不同病理状态下患者替考拉宁目标C_min的确定,为临床治疗中替考拉宁TDM、个体化给药提供参考。

Objective To make rational use of teicoplanin and better management of patients treated with teicoplanin. Methods Nine clinical issues related to the treatment of teicoplanin in Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (Japan, 2022) were interpreted from the perspective of pharmacy. Results The guidelines indicated that the area under drug-time curve/minimum inhibitory concentration was the key pharmacokinetic/pharmacodynamic parameters of teicoplanin.The purpose of therapeutic drug monitoring (TDM) of teicoplanin is to specify the target trough concentration (C_min), which guidelines recommend for severe or complex methicillin-resistant Staphylococcus aureus (MRSA) infection is 20-40 mg/L.The target C_min for uncomplicated MRSA infection with normal or mildly impaired renal function is 15-30 mg/L.For severe and/or complex MRSA infections, such as infective endocarditis and osteomyelitis, the C_min of teicoplanin was 20-40 mg/L. Conclusions The guidelines are aimed at the determination of target C_min of teicoplanin in patients with different pathological conditions, and provide reference for individual drug administration and teicoplanin TDM in clinical treatment.

目的 探究多囊卵巢综合征不孕患者采用定经汤加减联合穴位埋线治疗的临床价值。方法 研究对象为我院2020年3月—2021年3月收治的90例多囊卵巢综合征不孕患者,并采取随机抽签法分为对照组和研究组,对照组枸橼酸氯米芬胶囊治疗,研究组采用定经汤加减联合穴位埋线法治疗。对比2组患者治疗效果。结果 对比2组患者激素水平,干预前,对照组患者睾酮素(T)、黄体生成激素(LH)、卵泡生成激素(FSH)水平与研究组差异不具有统计学意义(P>0.05);干预后,研究组在改善FSH、LH、T水平方面优于对照组(P<0.05);干预前,2组患者中医症状积分对比差异不具有统计学意义(P>0.05);干预后,研究组患者中医证候分析较对照组改善(P<0.05);对照组患者子宫内膜厚度、排卵率及妊娠率均低于研究组患者(P<0.05)。结论 定经汤加减联合穴位埋线能够有效改善多囊卵巢综合征不孕患者性激素水平,促进排卵、提高临床妊娠率,具备临床应用价值。

目的 本文主要分析乳腺癌患者应用蒽环类药物序贯曲妥珠单抗治疗对其心脏毒性的相关危险因素,并按照危险因素选择合适患者的治疗方案。方法 研究纳入了2019年6月—2022年6月在本院接受治疗的300例乳腺癌患者,患者接受蒽环类药物序贯曲妥珠单抗治疗,按照患者治疗期间是否发生心脏毒性进行分组,即为11例发生心脏毒性(观察组),289例患者未发生心脏毒性(对照组)。记录2组患者个人基础资料、肿瘤分期、病史、蒽环类药物以及联合化疗等因素,通过Logistic回归逐一对各项因素展开分析,了解相关危险因素。结果 在本次研究分析中,心脏毒性发生例数为11例,发生率为3.67%。其中289例患者未出现心脏毒性,患者用药后未出现相关反应。2组患者在联合放疗、高脂血症、蒽环类药物种类均有差异,差异有统计学意义(P<0.05)。结论 乳腺癌患者应用蒽环类药物序贯曲妥珠单抗后,发生心脏毒性的几率升高,其危险因素主要包括高脂血症史、应用表柔比星治疗以及左胸放疗史。

目的 探讨达格列净辅助治疗老年心力衰竭合并2型糖尿病(T2DM)患者的效果。方法 将我院2020年9月—2022年2月期间收治的82例老年心力衰竭合并T2DM患者按照随机数字表法分为观察组和对照组,对照组41例予以常规降糖及抗心力衰竭药物治疗,观察组41例在对照组基础上予以达格列净治疗,观察2组患者血糖水平、心肌损伤标志物、心室结构以及不良反应。结果 治疗3个月后,观察组空腹血糖、餐后2小时血糖、糖化血红蛋白水平低于对照组(P<0.05);观察组NT-proBNP、AngⅡ水平低于对照组(P<0.05);观察组LAVI、LVESd、LVEDd低于对照组,观察组LVEF高于对照组(P<0.05);观察组不良反应发生率(12.20%)与对照组(7.32%)对比差异无统计学意义(P>0.05)。结论 达格列净辅助治疗老年心力衰竭合并T2DM患者有效降低血糖,减轻心肌损伤,改善心脏结构和功能,且不增加患者不良反应发生率。

目的 探讨小儿肠套叠超声引导下水压灌肠复位治疗的价值。方法 将我院2020年2月—2022年5月期间收治的122例肠套叠患儿按照随机数字表法分为观察组和对照组,对照组61例予以X射线引导下空气灌肠复位治疗,观察组61例予以超声引导下水压灌肠复位治疗,观察2组患儿治疗效果、胃肠激素、应激反应、并发症发生率以及复发率。结果 观察组复位成功率(98.36%)高于对照组(86.89%),复位时间、大便隐血消失时间、肠功能恢复时间、住院时间短于对照组(P<0.05);观察组胃泌素、胃动素水平低于对照组(P<0.05);观察组白细胞、降钙素原、C-反应蛋白水平低于对照组(P<0.05);观察组并发症总发生率(3.28%)低于对照组(14.75%)(P<0.05);观察组复发率(3.28%)低于对照组(13.11%)(P<0.05)。结论 超声引导下水压灌肠复位治疗小儿肠套叠有助于调节胃肠激素水平,减轻炎症反应,提高复位成功率,缩短手术时间,加快肠道恢复,降低复发率和并发症发生率。

目的 探究中医药治疗盆腔炎的用药规律,为中医临床辩证用药提供借鉴。方法 采用主题词联合自由词相,全面检索CNKI、VIP、Wangfang、CBM、PubMed和EMbase、数据库及Cochrane图书馆,收集中、西药对比治疗盆腔炎的随机对照试验。严格按照纳入、排除标准挑选随机对照试验中涵盖的中药药方,采用Excel表格统计分析药方中药的四气、五味、归经和用药频率,随后利用系统聚类软件对使用频率高的中药开展关联、聚类和主成分分析。结果 本文共纳入235个随机对照试验,涉及320首中药处方,平均用药味数13.29味,使用频率前五位的药分别为延胡索、赤芍、当归、蒲公英、丹参;关联规则共得出41对高关联药对,其中包括赤芍-延胡索、莪术-三棱-败酱草等。高频率使用的前30味中药可分为五大类,获取的9个主成分分析结果与系统聚类中的结果一致。结论 本研究采用循证医学和系统聚类分析方法,剖析中医药治疗盆腔炎的用药规律,为临床用药提供参考。

Objective To discuss the medication regularity of traditional Chinese medicine (TCM) in the treatment of pelvic inflammatory disease, and provide new thinking for effective medication in clinical medicine. Methods Keywords combined with free word were used to comprehensively search CNKI, VIP, Wangfang, CBM, PubMed and EMbase, databases and Cochrane library to collect randomized controlled trials of comparative treatment of pelvic inflammatory disease between Chinese and Western drugs. The TCM prescriptions covered in the randomized controlled trial were selected in strict accordance with the standard inclusion and exclusion criteria. Excel was used to statistically analyze the four properties, five flavors, meridian and medication frequency of TCM prescriptions. Then, systematic clustering software was used to carry out correlation, clustering and principal component analysis for the Chinese medicines with high using frequency. Results The study included 235 randomized controlled trial and 320 prescriptions of traditional Chinese medicine were involved, the average number of herbs was 13.29, which Yanhusuo, Chishao, Danggui, Pugongying, Danshen were with top five frequency. A total of 41 drug pairs with high association were obtained by association rules, including Chishao-Yanhusuo, Eshu-Sanleng-Baijiangcao, etc. Thirty traditional Chinese medicine with high using frequency can be divided into 5 categories according to the effect. The obtained results of 9 principal component analysis were consistent with those in the system cluster. Conclusions In this study, evidence-based medicine and systematic cluster analysis were used to analyze the medication regularity of traditional Chinese medicine in the treatment of pelvic inflammatory disease, so as to provide reference for the clinical medication.

目的 探讨加味益气固冲汤在生育期血瘀证崩漏患者治疗中的应用价值及对雌激素水平的影响。方法 按照随机数字表法将2018年11月—2021年1月我院符合诊断标准及选例标准的112例生育期血瘀证崩漏患者分为常规组、实验组,每组56例。常规组予以基础治疗,实验组在常规组基础上采用加味益气固冲汤治疗。比较2组治疗效果、不良反应情况、治疗前后经期出血量、子宫内膜厚度、雌激素水平及血液流变学指标。结果 同常规组总有效率82.14%相比,实验组96.43%较高(P＜0.05);治疗后实验组经期出血量、子宫内膜厚度改善幅度大于常规组(P＜0.05);治疗后实验组黄体生成素、孕酮、卵泡刺激素、雌二醇水平较常规组低(P＜0.05);治疗后实验组红细胞聚集指数、纤维蛋白原、全血低切黏度、血浆黏度均小于常规组(P＜0.05);实验组不良反应总发生率5.36%与常规组10.71%对比,无差异(P＞0.05)。结论 加味益气固冲汤联合西药治疗生育期血瘀证崩漏患者效果显著,调节性激素水平,改善子宫形态,改善血液微循环,缓解经期出血症状。

Objective To explore the application value of Jiawei Yiqi Guchong Decoction in the treatment of patients with blood stasis syndrome of metrorrhagia and metrostaxis and its influence on estrogen level. Methods According to the random number table method, 112 patients with blood stasis syndrome of metrorrhagia and metrostaxis in their reproductive period, who met the diagnostic criteria and case selection criteria in our hospital from November 2018 to January 2021, were divided into conventional group and experimental group, with 56 cases in each group. The conventional group was given basic treatment, and the experimental group was treated with Jiawei Yiqi Guchong Decoction on the basis of the conventional group. The treatment effect, adverse reactions, menstrual bleeding, endometrial thickness, estrogen level and hemorheology indexes before and after treatment were compared between the two groups. Results The total effective rate of experimental group was 96.43%, higher than that of conventional group (82.14%, P<0.05). After treatment, the improvement of menstrual bleeding and endometrial thickness in the experimental group was greater than that in the conventional group (P<0.05). After treatment, the levels of luteinizing hormone, progesterone, follicle stimulating hormone and estradiol in the experimental group were lower than those in the conventional group (P<0.05). After treatment, erythrocyte aggregation index, fibrinogen, whole blood low shear viscosity and plasma viscosity in the experimental group were lower than those in the conventional group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the experimental group (5.36%) and the conventional group (10.71%, P>0.05). Conclusions Jiawei Yiqi Guchong Decoction combined with Western medicine had a significant effect on the treatment of patients with blood stasis syndrome of metrorrhagia and metrostaxis in reproductive period, which can regulate the levels of sex hormones, improve the morphology of uterus, blood microcirculation and relieve the symptoms of menstrual bleeding.

目的 探索心脏康复干预对房颤合并高血压患者的血脂血压变化、运动耐量、心脏功能、肺功能等指标的影响。方法 选取房颤合并高血压患者96例,随机分为常规治疗组和心脏康复(CR)组,每组各48例患者。常规治疗组给予规范的药物治疗,CR组在规范药物治疗的基础上予运动干预6个月,对比治疗前后2组甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)水平,左心房直径(LA)、左心室射血分数(LVEF)、左心室舒张末内径(LVEDd),无氧阈值(AT)、峰值公斤摄氧量(PeakVO₂/kg)、峰值通气量(VEpeak)、每搏输出量(SV)、峰值氧脉搏(PeakO₂pluse),收缩压(SBP)与舒张压(DBP)变化情况,6分钟步行距离(6MWD),以及Borg劳累评估量表评分、焦虑自评量表(SAS)和抑郁自评量表(SDS)评分。结果 2组患者治疗6个月时,TC、TG、LDL-C水平以及SBP、DBP均下降(P<0.05),但2组之间比较,3项血脂指标无统计学差异(P>0.05),而CR组血压显著下降(P<0.05) 。2组患者治疗6个月时,LA、LVEDd减小(P<0.05),而LVEF无变化(P>0.05),CR组LA较常规治疗组缩小(P<0.05)。治疗6个月时,CR组AT、PeakVO₂/kg、VEpeak、SV和PeakO₂plus水平均升高(P<0.05),而常规治疗组的上述相关指标无明显变化(P>0.05)。治疗6个月时,2组患者6分钟步行距离均增加,CR组较常规组增加(P<0.05)。治疗6个月时,CR组Borg劳累评估量表评分、SAS评分及SDS评分均下降,而常规治疗组上述3项评分较治疗前无变化(P>0.05),与常规治疗组比较,CR组上述3项评分降低(P<0.05)。结论 以中等强度运动干预为主导的心脏康复治疗能够降低房颤合并高血压患者的血脂水平、控制血压状态、改善左心房及左心室结构重构,还可以增加该群体的运动耐力及心肺功能、减少消极情绪并提高生活质量。

Objective To evaluate the impact of cardiac rehabilitation on blood lipid level,blood pressure control,exercise endurance,cardiac function, quality of life and lung function in patients with hypertension and atrial fibrillation (AF). Methods This prospective cohort study enrolled 96 patients with AF and hypertension, who were randomly and evenly assigned to the conventional group and the cardiac rehabilitation (CR) group, both treated for at least 6 months. Research indicators included the levels of triglycerides (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C); left atrial diameter (LA), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDd), anaerobic threshold (AT), peak oxygen uptake volume per kilogram (PeakVO₂/kg), peak ventilation volume (VEpeak), stroke volume (SV), peak oxygen pulse (PeakO₂pluse), changes in blood pressure, 6 minutes walking distance, Borg Fatigue Scale score, Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores. Results At the 6th month of the treatment, the levels of TG, TC, LDL-C, systolic blood pressure (SBP), diastolic blood pressure (DBP) were significantly reduced (P<0.05) in both groups. However, there was no statistical difference among the three blood lipid indicators between the conventional group and the CR group after treatment (P>0.05). Blood pressure dropped significantly(P<0.05) in both groups, especially in the CR group. Meanwhile, after treatment, LA and LVEDd decreased significantly (P<0.05) in both groups, except LVEF. LA decreased significantly (P<0.05) in CR group, compared with conventional group. In addition, AT, PeakVO₂/kg, VEpeak, SV and PeakO₂pluse levels were significantly elevated (P<0.05) in CR group compared with the conventional group after the treatment. There was no significant difference (P>0.05) in the indicators above in the conventional group. Six minutes walking distance were significantly increased (P<0.05) in both groups at 6th month of treatment, compared with the conventional group, the CR group increased more (P<0.05). Borg Fatigue Scale score, SAS score and SDS score were significantly reduced (P<0.05) in CR group at 6th month of treatment, however, there was no statistical difference (P>0.05) in the conventional group compared with that before treatment. The scores above were significantly reduced (P<0.05) in CR group compared with the conventional group after the treatment. Conclusions Cardiac rehabilitation therapy dominated by moderate-intensity exercise intervention can reduce the blood lipid level of atrial fibrillation and hypertension patients, control the blood pressure, improve the left atrial and left ventricular structure reconstruction, increase the exercise endurance, improve cardiopulmonary function, reduce negative emotions and improve the quality of life.

分泌性中耳炎（SOM）的临床特征表现为听力下降和中耳积液,与中耳化脓性炎症常伴随耳部急性感染不同,SOM常伴随耳部闷胀、轻微耳痛等,致使听力出现障碍。SOM发病机制较为复杂,可能与感染、免疫、咽鼓管功能障碍等多种因素相关,治疗方法也因此呈现出多样化的特点。本文就SOM的病因病机及其治疗方式展开综述,以期为临床及早诊断和治疗SOM提供理论依据。

The clinical characteristics of secretory otitis media（SOM）are hearing loss and effusion in the middle ear．Different from acute ear infection of suppurative inflammation in the middle ear,SOM is often accompanied by ear tightness and mild earache,resulting in hearing impairment．The pathogenesis of SOM is complex,which may be related to infection,immunity,eustachian tube dysfunction and other factors．Therefore,the treatment methods are diversified．This paper reviews the etiology,pathogenesis and treatment of SOM,in order to provide theoretical basis for clinical early diagnosis and treatment of SOM.

目的 探讨噻托溴铵/奥达特罗对C、D组慢性阻塞性肺疾病（COPD）稳定期患者的临床治疗效果。方法 选取2021年1月—2021年10月期间本院收治的C、D 组COPD稳定期患者70例,按照随机数字表达均分为研究组（35例）和对照组（35例）。研究组给予噻托溴铵/奥达特罗雾化吸入治疗,对照组采取规律吸入布地奈德/福莫特罗粉治疗。均持续6个月治疗。比较2组一般资料、治疗前后肺功能指标、住院时间、mMRC评分、CAT评分、急性发作和糖皮质激素使用时间,以及不良反应。结果 治疗6个月后,研究组的肺功能指标包括第1秒用力呼气容积（FEV₁）、FEV1%预计值（FEV₁%pred）、用力肺活量（FVC）以及FEV₁/ FVC比值相比对照组均改善（均P< 0.05）。且相比对照组,研究组患者住院时间更短、治疗后mMRC评分和CAT评分更低、急性发作和糖皮质激素使用时间>30 d的例数更少（均P< 0.05）。此外,研究组患者治疗期间口干、恶心/呕吐、声音嘶哑和口腔感染的不良反应总发生率相比对照组更低。结论 噻托溴铵/奥达特罗能有效改善C、D 组COPD稳定期患者肺功能和临床症状,缩短住院时间和激素使用时间,减少急性发作和不良反应发生率,降低患者的治疗费用。